Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMXLE71)

Drug Name
SYL-040012 Drug Info
Synonyms SYL-0012; Beta 2 adrenoceptor-targeting siRNA (ocular hypertension), Sylentis
Indication
Disease Entry ICD 11 Status REF
Ocular hypertension 9C61.01 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMXLE71

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
ADRB2 messenger RNA (ADRB2 mRNA) TTG8ZWP ADRB2_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
ADRB2 messenger RNA (ADRB2 mRNA) DTT ADRB2 7.09 5.67 5.558 5.603
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Ocular hypertension
ICD Disease Classification 9C61.01
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
ADRB2 messenger RNA (ADRB2 mRNA) DTT ADRB2 1.10E-01 0.55 0.97
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT02250612) SYL040012, Treatment for Open Angle Glaucoma. U.S. National Institutes of Health.
2 In vitro and in vivo efficacy of SYL040012, a novel siRNA compound for treatment of glaucoma. Mol Ther. 2014 Jan;22(1):81-91.